RU2007102292A - Способ лечения расстройств и заболеваний нервной системы - Google Patents
Способ лечения расстройств и заболеваний нервной системы Download PDFInfo
- Publication number
- RU2007102292A RU2007102292A RU2007102292/14A RU2007102292A RU2007102292A RU 2007102292 A RU2007102292 A RU 2007102292A RU 2007102292/14 A RU2007102292/14 A RU 2007102292/14A RU 2007102292 A RU2007102292 A RU 2007102292A RU 2007102292 A RU2007102292 A RU 2007102292A
- Authority
- RU
- Russia
- Prior art keywords
- disorder
- syndrome
- disease
- azabicyclo
- hexane
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims 18
- 201000010099 disease Diseases 0.000 title claims 9
- 210000000653 nervous system Anatomy 0.000 title claims 8
- 208000035475 disorder Diseases 0.000 claims 8
- 208000002193 Pain Diseases 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 5
- 208000011580 syndromic disease Diseases 0.000 claims 5
- OFYVIGTWSQPCLF-UHFFFAOYSA-N 1-(4-methylphenyl)-3-azabicyclo[3.1.0]hexane Chemical compound C1=CC(C)=CC=C1C1(CNC2)C2C1 OFYVIGTWSQPCLF-UHFFFAOYSA-N 0.000 claims 4
- 208000024827 Alzheimer disease Diseases 0.000 claims 4
- 208000000044 Amnesia Diseases 0.000 claims 4
- BSMNRYCSBFHEMQ-UHFFFAOYSA-N dov-216,303 Chemical compound C1=C(Cl)C(Cl)=CC=C1C1(CNC2)C2C1 BSMNRYCSBFHEMQ-UHFFFAOYSA-N 0.000 claims 4
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 claims 4
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 claims 4
- 208000024891 symptom Diseases 0.000 claims 4
- 230000001457 vasomotor Effects 0.000 claims 4
- 208000000094 Chronic Pain Diseases 0.000 claims 3
- 201000000980 schizophrenia Diseases 0.000 claims 3
- 208000008811 Agoraphobia Diseases 0.000 claims 2
- 201000000736 Amenorrhea Diseases 0.000 claims 2
- 206010001928 Amenorrhoea Diseases 0.000 claims 2
- 208000031091 Amnestic disease Diseases 0.000 claims 2
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 2
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 2
- 206010003805 Autism Diseases 0.000 claims 2
- 208000020706 Autistic disease Diseases 0.000 claims 2
- 206010008190 Cerebrovascular accident Diseases 0.000 claims 2
- 206010010071 Coma Diseases 0.000 claims 2
- 208000034347 Faecal incontinence Diseases 0.000 claims 2
- 208000001640 Fibromyalgia Diseases 0.000 claims 2
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 claims 2
- 201000006792 Lennox-Gastaut syndrome Diseases 0.000 claims 2
- 208000026139 Memory disease Diseases 0.000 claims 2
- 208000027030 Premenstrual dysphoric disease Diseases 0.000 claims 2
- 208000028017 Psychotic disease Diseases 0.000 claims 2
- 206010039966 Senile dementia Diseases 0.000 claims 2
- 208000006011 Stroke Diseases 0.000 claims 2
- 208000000323 Tourette Syndrome Diseases 0.000 claims 2
- 208000016620 Tourette disease Diseases 0.000 claims 2
- 208000003443 Unconsciousness Diseases 0.000 claims 2
- 239000000670 adrenergic alpha-2 receptor antagonist Substances 0.000 claims 2
- 231100000540 amenorrhea Toxicity 0.000 claims 2
- 230000006986 amnesia Effects 0.000 claims 2
- 230000037007 arousal Effects 0.000 claims 2
- 208000026106 cerebrovascular disease Diseases 0.000 claims 2
- 206010016256 fatigue Diseases 0.000 claims 2
- 230000002267 hypothalamic effect Effects 0.000 claims 2
- 230000006984 memory degeneration Effects 0.000 claims 2
- 208000023060 memory loss Diseases 0.000 claims 2
- 208000022610 schizoaffective disease Diseases 0.000 claims 2
- 230000001568 sexual effect Effects 0.000 claims 2
- 208000019116 sleep disease Diseases 0.000 claims 2
- 208000022925 sleep disturbance Diseases 0.000 claims 2
- 208000027765 speech disease Diseases 0.000 claims 2
- 201000006347 Intellectual Disability Diseases 0.000 claims 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 claims 1
- 206010048010 Withdrawal syndrome Diseases 0.000 claims 1
- 208000030963 borderline personality disease Diseases 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 claims 1
- 230000001149 cognitive effect Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 208000004296 neuralgia Diseases 0.000 claims 1
- 208000021722 neuropathic pain Diseases 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Anesthesiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Nutrition Science (AREA)
- Pain & Pain Management (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US59020304P | 2004-07-22 | 2004-07-22 | |
| US60/590,203 | 2004-07-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2007102292A true RU2007102292A (ru) | 2008-08-27 |
Family
ID=35149631
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2007102292/14A RU2007102292A (ru) | 2004-07-22 | 2005-07-21 | Способ лечения расстройств и заболеваний нервной системы |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20060020015A1 (OSRAM) |
| EP (1) | EP1773320A1 (OSRAM) |
| JP (1) | JP2008507550A (OSRAM) |
| KR (1) | KR20070034126A (OSRAM) |
| CN (1) | CN101410106A (OSRAM) |
| AU (1) | AU2005266994A1 (OSRAM) |
| BR (1) | BRPI0512186A (OSRAM) |
| CA (1) | CA2574310A1 (OSRAM) |
| IL (1) | IL180731A0 (OSRAM) |
| MX (1) | MX2007000853A (OSRAM) |
| NO (1) | NO20070912L (OSRAM) |
| RU (1) | RU2007102292A (OSRAM) |
| WO (1) | WO2006012474A1 (OSRAM) |
| ZA (1) | ZA200700578B (OSRAM) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080081834A1 (en) | 2002-07-31 | 2008-04-03 | Lippa Arnold S | Methods and compositions employing bicifadine for treating disability or functional impairment associated with acute pain, chronic pain, or neuropathic disorders |
| BRPI0512182A (pt) * | 2004-07-22 | 2008-02-19 | Wyeth Corp | método para o tratamento de condições e desordens do sistema nervoso |
| EP1773321A2 (en) * | 2004-07-22 | 2007-04-18 | Wyeth | Method for treating nervous system disorders and conditions |
| US8000005B2 (en) * | 2006-03-31 | 2011-08-16 | Prysm, Inc. | Multilayered fluorescent screens for scanning beam display systems |
| EP1904059A2 (en) * | 2005-07-21 | 2008-04-02 | Wyeth a Corporation of the State of Delaware | Method for treating nervous system disorders and conditions |
| US20080033050A1 (en) | 2006-08-04 | 2008-02-07 | Richards Patricia Allison Tewe | Method of treating thermoregulatory disfunction with paroxetine |
| US9566264B2 (en) | 2013-07-01 | 2017-02-14 | Euthymics Bioscience, Inc. | Combinations and methods |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3166571A (en) * | 1962-06-06 | 1965-01-19 | American Cyanamid Co | 1-phenyl-1, 2-cyclopropane dicarboximides |
| US3344026A (en) * | 1966-05-16 | 1967-09-26 | American Cyanamid Co | Dosage unit composition of 1-(p-chlorophenyl)-1, 2-cyclopropanedicarboximide for relief of depression |
| US3892772A (en) * | 1973-12-04 | 1975-07-01 | American Cyanamid Co | Isomer of 1-(p-chlorophenyl)-1,2-cyclopropanedicarboximide and method of use |
| US4088652A (en) * | 1975-07-31 | 1978-05-09 | American Cyanamid Company | Acylazabicyclohexanes |
| US4131611A (en) * | 1975-07-31 | 1978-12-26 | American Cyanamid Company | Azabicyclohexanes |
| US4118417A (en) * | 1977-06-23 | 1978-10-03 | American Cyanamid Company | Process for resolving cis-1-substituted phenyl-1,2-cyclopropanedicarboxylic acids |
| US4118393A (en) * | 1977-06-23 | 1978-10-03 | American Cyanamid Company | Phenyl azabicyclohexanones |
| GR72713B (OSRAM) * | 1976-09-15 | 1983-12-01 | American Cyanamid Co | |
| US4435419A (en) * | 1981-07-01 | 1984-03-06 | American Cyanamid Company | Method of treating depression using azabicyclohexanes |
| DE3378208D1 (en) * | 1982-12-21 | 1988-11-17 | Ciba Geigy Ag | Substituted azabicycloalkanes, their use, pharmaceutical preparations containing these compounds and process for preparing these compounds |
| US6204284B1 (en) * | 1991-12-20 | 2001-03-20 | American Cyanamid Company | Use of 1-(substitutedphenyl)-3-azabicyclo[3.1.0]hexanes for the treatment of chemical dependencies |
| US6756388B1 (en) * | 1993-10-12 | 2004-06-29 | Pfizer Inc. | Benzothiophenes and related compounds as estrogen agonists |
| US6486177B2 (en) * | 1995-12-04 | 2002-11-26 | Celgene Corporation | Methods for treatment of cognitive and menopausal disorders with D-threo methylphenidate |
| US6150376A (en) * | 1998-08-05 | 2000-11-21 | Georgetown University | Bi- and tri-cyclic aza compounds and their uses |
| DE19919336A1 (de) * | 1999-04-27 | 2000-11-16 | Consortium Elektrochem Ind | Verfahren zur Ringspaltung von Thiazolidinderivaten |
| US6372919B1 (en) * | 2001-01-11 | 2002-04-16 | Dov Pharmaceutical, Inc. | (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as an anti-depressant agent |
| DE60221642T3 (de) * | 2001-02-12 | 2017-10-26 | Wyeth LLC (n.d.Ges.d. Staates Delaware) | O-desmethyl-venlafaxine succinat salz |
| EP1266659A1 (en) * | 2001-06-11 | 2002-12-18 | Pantarhei Bioscience B.V. | Pyridoxal in combination with serotonin re-uptake inhibitor for the treatment of hot flushes |
| US6569887B2 (en) * | 2001-08-24 | 2003-05-27 | Dov Pharmaceuticals Inc. | (−)-1-(3,4-Dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as a dopamine-reuptake |
| UA77234C2 (en) * | 2001-12-05 | 2006-11-15 | Wyeth Corp | Monohydrate of venlafaxine hydrochloride and methods for its preparation (variants) |
| RU2004120285A (ru) * | 2001-12-05 | 2005-04-10 | Уайт (Us) | Новый кристаллический полиморф гидрохлорида венлафаксина и способы его получения |
| US20040152710A1 (en) * | 2002-10-15 | 2004-08-05 | Deecher Darlene Coleman | Use of norepinephrine reuptake modulators for preventing and treating vasomotor symptoms |
| FR2851163B1 (fr) * | 2003-02-14 | 2007-04-27 | Utilisation de l'enantiomere dextrogyre du milnacipran pour la preparation d'un medicament | |
| EP1773321A2 (en) * | 2004-07-22 | 2007-04-18 | Wyeth | Method for treating nervous system disorders and conditions |
-
2005
- 2005-07-21 AU AU2005266994A patent/AU2005266994A1/en not_active Abandoned
- 2005-07-21 EP EP05773617A patent/EP1773320A1/en not_active Withdrawn
- 2005-07-21 CN CNA2005800316183A patent/CN101410106A/zh active Pending
- 2005-07-21 BR BRPI0512186-8A patent/BRPI0512186A/pt not_active IP Right Cessation
- 2005-07-21 JP JP2007522782A patent/JP2008507550A/ja active Pending
- 2005-07-21 KR KR1020077004076A patent/KR20070034126A/ko not_active Abandoned
- 2005-07-21 WO PCT/US2005/025974 patent/WO2006012474A1/en not_active Ceased
- 2005-07-21 US US11/186,279 patent/US20060020015A1/en not_active Abandoned
- 2005-07-21 CA CA002574310A patent/CA2574310A1/en not_active Abandoned
- 2005-07-21 MX MX2007000853A patent/MX2007000853A/es unknown
- 2005-07-21 RU RU2007102292/14A patent/RU2007102292A/ru not_active Application Discontinuation
-
2007
- 2007-01-16 IL IL180731A patent/IL180731A0/en unknown
- 2007-01-19 ZA ZA200700578A patent/ZA200700578B/xx unknown
- 2007-02-16 NO NO20070912A patent/NO20070912L/no unknown
-
2011
- 2011-01-06 US US12/985,871 patent/US20120010260A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0512186A (pt) | 2008-02-19 |
| WO2006012474A1 (en) | 2006-02-02 |
| KR20070034126A (ko) | 2007-03-27 |
| EP1773320A1 (en) | 2007-04-18 |
| AU2005266994A1 (en) | 2006-02-02 |
| JP2008507550A (ja) | 2008-03-13 |
| MX2007000853A (es) | 2007-03-26 |
| CN101410106A (zh) | 2009-04-15 |
| CA2574310A1 (en) | 2006-02-02 |
| US20060020015A1 (en) | 2006-01-26 |
| IL180731A0 (en) | 2007-07-04 |
| NO20070912L (no) | 2007-04-20 |
| US20120010260A1 (en) | 2012-01-12 |
| ZA200700578B (en) | 2010-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Lembo et al. | T1390 rifaximin for the treatment of diarrhea-associated irritable bowel syndrome: short term treatment leading to long term sustained response | |
| JP2006117689A (ja) | 置換フェネチルアミン類を用いた医薬組成物 | |
| CA2889855A1 (en) | Methods for treating fibromyalgia | |
| JP2008545795A (ja) | 睡眠覚醒障害の治療 | |
| RU2007102292A (ru) | Способ лечения расстройств и заболеваний нервной системы | |
| JP2008512433A (ja) | 炎症性障害及び疼痛の治療 | |
| JPH07508281A (ja) | 光学的に純粋な（＋）シブトラミンを用いるうつ病およびその他の障害を治療する方法ならびに組成物 | |
| RU2007102291A (ru) | Способ лечения расстройств и заболеваний нервной системы | |
| US20170151197A1 (en) | Lauflumide and the enantiomers thereof, method for preparing same and therapeutic uses thereof | |
| JP2008507550A5 (OSRAM) | ||
| JP5553955B2 (ja) | 鬱病の処置のための蘇生薬モダフィニルおよび抗鬱薬の組み合わせ | |
| KR20060023122A (ko) | 우울증의 치료를 위한 흥분성 모다피닐 및 항우울제의배합물 | |
| JP2007506731A (ja) | Ｎｐｙｙ５受容体アンタゴニストによる急速眼球運動（ｒｅｍ）睡眠妨害に関連する神経障害の治療 | |
| RU2007102290A (ru) | Способ лечения нарушений и заболеваний нервной системы | |
| WO2009127737A1 (en) | Use of enantiomer (1s, 2r) of milnacipran hydrochloride for the preventive treatment of suicidal behaviour in depressed patients | |
| US20240226591A1 (en) | Major depressive disorder or persistent depressive disorder prevention or treatment with low intensity and high frequency magnetic stimulation | |
| Dannon | Kleptomania: An impulse control disorder? | |
| Daly | The use of stimulants in the treatment of post traumatic stress disorder: case report | |
| Goldberg et al. | T1389 TD-5108, a selective 5-HT4 agonist, is consistently better than placebo regardless of response definition in patients with chronic constipation | |
| Hanlon et al. | Management of severe behavioural dyscontrol following subarachnoid haemorrhage | |
| MXPA01001179A (es) | Metodos y composiciones para el uso de la moclobemida. | |
| Alper | Do antidepressants improve or worsen seizures in patients with epilepsy | |
| CA2585560C (en) | Use of acetyl l-carnitine for the treatment of fibromyalgic syndrome | |
| Hooten | Chronic pain and depression | |
| Azorin | P. 7. c. 004 Valproate in the treatment of acute mania in adolescents with bipolar disorder |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20090905 |